Phase III Trial of Enzastaurin for NHL Patients Initiated

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Phase III Trial of Enzastaurin for NHL Patients Initiated

INDIANAPOLIS—Eli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content